CDDO-EA(Synonyms: CDDO ethyl amide; TP319; RTA 405)

发表于2024年10月15日由上海金畔生物科技有限公司

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDDO-EA (Synonyms: CDDO ethyl amide; TP319; RTA 405) 纯度: 98.46%

CDDO-EA 是一种 NF-E2 相关因子 2 /抗氧化反应元件 (Nrf2/ARE) 激活剂。

CDDO-EA Chemical Structure

CAS No. : 932730-51-3

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥2967	In-stock
5 mg	￥2600	In-stock
10 mg	￥4700	In-stock
50 mg	￥14000	In-stock
100 mg	￥21000	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

CDDO-EA 相关产品

•相关化合物库:

Covalent Screening Library Plus
Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
NF-κB Signaling Compound Library
Stem Cell Signaling Compound Library
Anti-Cancer Compound Library
Anti-Aging Compound Library
Covalent Screening Library
Antioxidants Compound Library
Oxygen Sensing Compound Library
Ferroptosis Compound Library
Anti-Lung Cancer Compound Library
Transcription Factor Targeted Library

生物活性

CDDO-EA is an NF-E2 related factor 2/antioxidant response element (Nrf2/ARE) activator.

IC₅₀ & Target

Nrf2/ARE^[1]

体外研究
(In Vitro)

CDDO-EA potently activates Nrf2/ARE in a cell culture model of ALS and in the G93A SOD1 mouse model of ALS^[1]. CDDO-EA is a potent inducer of apoptosis in A549 lung cancer cells, as shown both by PARP cleavage and Annexin staining. CDDO-EA is more potent than CDDO itself as inducers of heme oxygenase-1 (HO-1). In RAW264.7 macrophage-like cells, CDDO-EA is 7-fold more potent than CDDO as suppressors of the ability of IFN-γ to induce iNOS^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

The survival analysis shows that G93A mice treated with CDDO-EA, compared to G93A littermate controls, lives significantly longer. CDDO-EA treatment increases the life-span by 20.6 days from 124.05±3.7 days to 144.72±8.1 days (16.6%) (p<0.001). In CDDO-EA-treated G93A mice, the age of death is 141.4±5.2 days and the duration from the age of onset to the age of death is 57.6±7.6 days, which means that the age of death from onset is prolonged by 17.5 days (43%)^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

518.73

Formula

C₃₃H₄₆N₂O₃

CAS 号

932730-51-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 34 mg/mL (65.54 mM)

* “≥” means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9278 mL	9.6389 mL	19.2779 mL
5 mM	0.3856 mL	1.9278 mL	3.8556 mL
10 mM	0.1928 mL	0.9639 mL	1.9278 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: 2.5 mg/mL (4.82 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (4.82 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.82 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.82 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.82 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.82 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
4.

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% saline

Solubility: 2.5 mg/mL (4.82 mM); Suspended solution; Need ultrasonic
5.

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.82 mM); Clear solution

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Neymotin A, et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med. 2011 Jul 1;51(1):88-96.

[2]. Liby K, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 2007 Mar 15;67(6):2414-9.

Cell Assay ^[1]	Wild-type and Nrf2−/− mouse embryonic fibroblasts are pre-treated with CDDO-EA or CDDO-TFEA at various concentrations (1, 10 and 100 nM in DMSO) for 18 hours and incubated with 2’,7’-Dichlorodihydrofluorecein diacetate (H2DCFDA) for 30 min. Cells are challenged with 250 µM tBHP for 15-30 min and the mean fluorescence intensity for ~10,000 cells is analyzed by FACSan flow cytometry using a 480-nm excitation wavelength and a 525-nm emission wavelength^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice^[1] G93A SOD1 transgenic familial ALS mice (high copy number) B6SJL background strain (G93A SOD1, B6SJL-TgGur1) are used. G93A transgenic mice are assigned randomly to the control (vehicle, mouse chaw only) and to mouse chaw containing either CDDO-EA or CDDO-TFEA (400 mg/kg of food, n=30 in both groups). This dose corresponds to about 80 mg/kg body weight/day, assuming each mouse consumes 5 grams of food per day. We found mice can tolerate this dose. Treatments started at two different time regimens: 1) “Early” at 30 days of age, about two months prior to symptom onset; 2) “At Onset” from the onset of the phenotype (80-90 days of age). A diet consisting of either 400 mg of CDDO-TFEA per kg of food or 400 mg of CDDO-EA per kg of food, and a control lab diet, are prepared by Purina. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Neymotin A, et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med. 2011 Jul 1;51(1):88-96. [2]. Liby K, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 2007 Mar 15;67(6):2414-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Bardoxolone(Synonyms: CDDO; RTA 401)

发表于2024年10月5日由上海金畔生物科技有限公司

Bardoxolone (Synonyms: CDDO; RTA 401) 纯度: 98.02%

Bardoxolone 是一种新型核调节因子 (Nrf-2)激活剂。

Bardoxolone Chemical Structure

CAS No. : 218600-44-3

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥870	In-stock
5 mg	￥800	In-stock
10 mg	￥1100	In-stock
50 mg	￥1950	In-stock
100 mg	￥3600	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

Bardoxolone 相关产品

•相关化合物库:

Covalent Screening Library Plus
Drug Repurposing Compound Library Plus
Clinical Compound Library Plus
Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
NF-κB Signaling Compound Library
Stem Cell Signaling Compound Library
Anti-Cancer Compound Library
Clinical Compound Library
Anti-Aging Compound Library
Drug Repurposing Compound Library
Covalent Screening Library
Antioxidants Compound Library
Oxygen Sensing Compound Library
Ferroptosis Compound Library
Medicine Food Homology Compound Library
Transcription Factor Targeted Library
Targeted Diversity Library
Rare Diseases Drug Library

生物活性

Bardoxolone is a novel nuclear regulator factor (Nrf-2) activator.

IC₅₀ & Target

Nrf-2^[1]

体外研究
(In Vitro)

Bardoxolone methyl, a novel synthetic triterpenoid and antioxidant inflammation modulator, potently induces Nrf2 and inhibits NF-κB and Janus-activated kinase/STAT signaling. Bardoxolone methyl has been shown to induce differentiation, inhibit proliferation, and induce apoptosis in cancer cell lines^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Kidney sections from Bardoxolone methyl-treated monkeys demonstrates decreased megalin protein expression despite similar mRNA expression across groups. The visualized decrease in megalin protein expression is confirmed by densitometry analyses, which demonstrated that Bardoxolone methyl administration significantly decreased megalin protein expression in the monkey kidney. Bardoxolone methyl administration does not affect the protein expression of cubilin in the kidney or the mRNA expression of cubilin in the kidney. The creatinine clearance in monkeys administered Bardoxolone methyl significantly differed from that at baseline and in vehicle-treated animals on day 28. After 28 days of Bardoxolone methyl administration, urinary albumin-to-creatinine ratios (UACRs), determined from the 24-hour urine collections, are significantly increased compared with those in animals receiving vehicle. Of note, UACRs decreases 53.3% in vehicle-treated animals and increased 27.9% in Bardoxolone methyl-treated monkeys^[3]. Male C57BL/6J mice are administered oral BARD during HFD feeding (HFD/BARD), only fed a high-fat diet (HFD), or fed low-fat diet (LFD) for 21 weeks. Compared with LFD mice, HFD mice have a marked increase in the number of F4/80 crown-like structures (+95%; p<0.001), which is effectively prevented by BARD (−50%; p<0.01). Similarly, the number of F4/80 interstitial macrophages is significantly higher in HFD mice by 98% (p<0.001) compared with LFD mice and by 32% (p<0.01) compared with HFD/BARD mice^[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

491.66

Formula

C₃₁H₄₁NO₄

CAS 号

218600-44-3

中文名称

巴多索隆

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 100 mg/mL (203.39 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0339 mL	10.1696 mL	20.3393 mL
5 mM	0.4068 mL	2.0339 mL	4.0679 mL
10 mM	0.2034 mL	1.0170 mL	2.0339 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.08 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.08 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. McCullough PA, et al. Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effectsof bardoxolone methyl. Drug Des Devel Ther. 2012;6:141-9.

[2]. Hong DS, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15;18(12):3396-406.

[3]. Reisman SA, et al. Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney. J Am Soc Nephrol. 2012 Oct;23(10):1663-73.

[4]. Dinh CH, et al. Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice. ScientificWorldJournal. 2015;2015:549352.

Animal Administration ^[3]^[4]	Monkeys^[3] Two separate studies are conducted in cynomolgus Monkeys. In one, cynomolgus Monkeys (n=9 per sex/dose group) are orally administered Bardoxolone methyl at 5, 30, and 300 mg/kg once daily for 12 months, with an interim analysis at 6 months and a postdose recovery analysis 4 weeks after the final dose, in a GLP environment. In a second study, female cynomolgus Monkeys (n=6 for vehicle and n=12 for treatment) are administered Bardoxolone methyl (30 mg/kg per day), as above, once daily for 28 days. Mice^[4] Male C57BL/6J mice are used. After 1 week of acclimatisation to the institutional animal facility (temperature 22°C, 12 h light/dark cycle), the animals are divided into three groups (n=7): (1) mice fed a normal diet (LFD group); (2) mice fed a high-fat diet (HFD group) (40% fat); and (3) mice fed the same HFD and supplemented with BARD in drinking water (10 mg/kg body weight) (HFD/BARD group). The dose and oral administration of BARD are chosen. After 21 weeks, all mice are euthanized using CO2 asphyxiation. Part of the mesenteric fat mass in each animal is collected and stored at −80°C for Western blot analysis. Another portion of the mesenteric fat depot is fixed in 4% paraformaldehyde and embedded in paraffin for the determination of morphology and immunohistochemistry. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. McCullough PA, et al. Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effectsof bardoxolone methyl. Drug Des Devel Ther. 2012;6:141-9. [2]. Hong DS, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15;18(12):3396-406. [3]. Reisman SA, et al. Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney. J Am Soc Nephrol. 2012 Oct;23(10):1663-73. [4]. Dinh CH, et al. Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice. ScientificWorldJournal. 2015;2015:549352.

Animal Administration
^[3]^[4]

Monkeys^[3]
Two separate studies are conducted in cynomolgus Monkeys. In one, cynomolgus Monkeys (n=9 per sex/dose group) are orally administered Bardoxolone methyl at 5, 30, and 300 mg/kg once daily for 12 months, with an interim analysis at 6 months and a postdose recovery analysis 4 weeks after the final dose, in a GLP environment. In a second study, female cynomolgus Monkeys (n=6 for vehicle and n=12 for treatment) are administered Bardoxolone methyl (30 mg/kg per day), as above, once daily for 28 days.
Mice^[4]
Male C57BL/6J mice are used. After 1 week of acclimatisation to the institutional animal facility (temperature 22°C, 12 h light/dark cycle), the animals are divided into three groups (n=7): (1) mice fed a normal diet (LFD group); (2) mice fed a high-fat diet (HFD group) (40% fat); and (3) mice fed the same HFD and supplemented with BARD in drinking water (10 mg/kg body weight) (HFD/BARD group). The dose and oral administration of BARD are chosen. After 21 weeks, all mice are euthanized using CO2 asphyxiation. Part of the mesenteric fat mass in each animal is collected and stored at −80°C for Western blot analysis. Another portion of the mesenteric fat depot is fixed in 4% paraformaldehyde and embedded in paraffin for the determination of morphology and immunohistochemistry.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. McCullough PA, et al. Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effectsof bardoxolone methyl. Drug Des Devel Ther. 2012;6:141-9.

[2]. Hong DS, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15;18(12):3396-406.

[3]. Reisman SA, et al. Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney. J Am Soc Nephrol. 2012 Oct;23(10):1663-73.

[4]. Dinh CH, et al. Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice. ScientificWorldJournal. 2015;2015:549352.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDDO-Im(Synonyms: RTA-403; TP-235; CDDO-Imidazolide)

发表于2024年5月17日由上海金畔生物科技有限公司

CDDO-Im (Synonyms: RTA-403; TP-235; CDDO-Imidazolide) 纯度: 98.19%

CDDO-Im (RTA-403) 是 Nrf2 和 PPAR 的活化剂，对 PPARα 和 PPARγ 的 K_i 分别为232 nM 和 344 nM。

CDDO-Im Chemical Structure

CAS No. : 443104-02-7

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥1788	In-stock
2 mg	￥1000	In-stock
5 mg	￥1500	In-stock
10 mg	￥2200	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

CDDO-Im 相关产品

•相关化合物库:

Covalent Screening Library Plus
Bioactive Compound Library Plus
Apoptosis Compound Library
Cell Cycle/DNA Damage Compound Library
Immunology/Inflammation Compound Library
NF-κB Signaling Compound Library
Stem Cell Signaling Compound Library
Anti-Cancer Compound Library
Anti-Aging Compound Library
Covalent Screening Library
Antioxidants Compound Library
Oxygen Sensing Compound Library
Ferroptosis Compound Library
Anti-Breast Cancer Compound Library
Anti-Blood Cancer Compound Library
Anti-Obesity Compound Library
Transcription Factor Targeted Library
Lipid Metabolism Compound Library

生物活性

CDDO-Im (RTA-403) is an activator of Nrf2 and PPAR, with K_is of 232 and 344 nM for PPARα and PPARγ^[1]^[2].

IC₅₀ & Target

PPARα

232 nM (Ki)

PPARγ

344 nM (Ki)

Nrf2

体外研究
(In Vitro)

CDDO-Im is highly active in suppressing cellular proliferation of human leukemia and breast cancer cell lines (IC₅₀ approximately 10-30 nM). In U937 leukemia cells, CDDO-Im also induces monocytic differentiation as measured by increased cell surface expression of CD11b and CD36^[1]. Treatment with CDDO-Im elevates protein levels of Nrf2, a transcription factor previously shown to bind ARE sequences, and increases expression of a number of antioxidant and detoxification genes regulated by Nrf2^[2]. CDDO-Im is one of the most potent synthetic triterpenoids shown to induce growth inhibition and apoptosis in various human cancer cells, including multiple myeloma, lung, pancreas and breast cancer. CDDO-Im treatment markedly induces cell cycle arrest at G2/M-phase and apoptosis in the triple-negative breast cancer cell lines, SUM159 and MDA-MB-231. The CD24−/EpCAM+ cells in SUM159 tumorspheres are significantly inhibited by CDDO-Im treatment. CDDO-Im also significantly decreases sphere forming efficiency and tumorsphere size in both primary and secondary sphere cultures^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

CDDO-Im is a potent inhibitor of de novo inducible nitric oxide synthase expression in primary mouse macrophages. Moreover, CDDO-Im inhibits growth of B16 murine melanoma and L1210 murine leukemia cells in vivo. Injection of 10 nM (5.4 μg) of CDDO-Im almost completely blocks the ability of IFN-γ to induce iNOS, and treatment with as little as 1 nmol of CDDO-Im (0.54 μg) is partially effective^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

541.72

Formula

C₃₄H₄₃N₃O₃

CAS 号

443104-02-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 50 mg/mL (92.30 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8460 mL	9.2299 mL	18.4597 mL
5 mM	0.3692 mL	1.8460 mL	3.6919 mL
10 mM	0.1846 mL	0.9230 mL	1.8460 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: 2.5 mg/mL (4.61 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (4.61 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (4.61 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (4.61 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.61 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.61 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
4.

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% saline

Solubility: 2.5 mg/mL (4.61 mM); Suspended solution; Need ultrasonic
5.

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (4.61 mM); Suspended solution; Need ultrasonic

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9(7):2798-806.

[2]. Liby K, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005 Jun 1;65(11):4789-98.

[3]. So JY, et al. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS One. 2014 Sep 17;9(9):e107616.

Cell Assay ^[3]	CDDO-Im is dissolved in DMSO. SUM159 and MDA-MB-231 cells are seeded into each well of 96-well plates (1,000 cell/well) and treated the next day with vehicle control or CDDO-Im (1, 10, 50, 100 and 200 nM) for given incubation time. The absorbance is measured with a spectrophotometer to determine cell proliferation rate^[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice: Mice are injected i.p. with thioglycollate, and the resulting resident peritoneal macrophages are activated 3 days later with an i.p. injection of IFN-γ. CDDO and CDDO-Im are injected i.p. 30 min after IFN-γ. Macrophages are harvested 10 h later, cultured for 12 h, and then assayed for expression of iNOS protein and production of nitric oxide (NO)^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9(7):2798-806. [2]. Liby K, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005 Jun 1;65(11):4789-98. [3]. So JY, et al. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS One. 2014 Sep 17;9(9):e107616.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDDO-2P-Im

发表于2024年2月17日由上海金畔生物科技有限公司

CDDO-2P-Im

CDDO-2P-Im 是 CDDO 咪唑胺类似物，具有化学预防作用。CDDO-2P-Im 可降低小鼠肺癌模型肺肿瘤的大小和严重程度。

CDDO-2P-Im Chemical Structure

CAS No. : 1883650-96-1

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥3810	询问价格 & 货期
5 mg	￥2800	询问价格 & 货期
10 mg	￥4500	询问价格 & 货期

* Please select Quantity before adding items.

CDDO-2P-Im 相关产品

•相关化合物库:

Covalent Screening Library Plus
Bioactive Compound Library Plus
Apoptosis Compound Library
Anti-Cancer Compound Library
Covalent Screening Library
Anti-Lung Cancer Compound Library

生物活性

CDDO-2P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-2P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model^[1].

体外研究
(In Vitro)

CDDO-2P-Im (100 nM; 4 days) induces differentiation of U937 cells at 100 nM^[1].
CDDO-2P-Im suppresses NO production in RAW264.7 cells with an IC₅₀ of 5.8 nM^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	U937 cells
Concentration:	30 nM, 100 nM
Incubation Time:	4 days
Result:	Induced differentiation of U937 cells at 100 nM.

体内研究
(In Vivo)

CDDO-2P-Im is more stable than CDDO-Im in pharmacokinetic studies^[1].
CDDO-2P-Im significantly elevates heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo^[1].
CDDO-2P-Im (50-200 mg/kg; diet; for 16 weeks) decreases the number, the size and the severity of tumors in A/J mice^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seven week-old female A/J mice^[1]
Dosage:	50 mg/kg, 200 mg/kg
Administration:	Diet; for 16 weeks
Result:	Decreased the number, the size and the severity of tumors.

分子量

618.81

Formula

C₃₉H₄₆N₄O₃

CAS 号

1883650-96-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 250 mg/mL (404.00 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6160 mL	8.0800 mL	16.1600 mL
5 mM	0.3232 mL	1.6160 mL	3.2320 mL
10 mM	0.1616 mL	0.8080 mL	1.6160 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (3.36 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.36 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47.

[2]. Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDDO-3P-Im

发表于2024年2月3日由上海金畔生物科技有限公司

CDDO-3P-Im 纯度: 98.19%

CDDO-3P-Im 是 CDDO 咪唑胺类似物，具有化学预防作用。CDDO-3P-Im 可降低小鼠肺癌模型肺肿瘤的大小和严重程度。CDDO-3P-Im 是一种具有口服活性的坏死 (necroptosis) 抑制剂，可用于缺血/再灌注 (I/R) 的研究。

CDDO-3P-Im Chemical Structure

CAS No. : 1883650-95-0

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥3810	In-stock
5 mg	￥2800	In-stock
10 mg	￥4500	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

CDDO-3P-Im 相关产品

•相关化合物库:

Covalent Screening Library Plus
Bioactive Compound Library Plus
Apoptosis Compound Library
Anti-Cancer Compound Library
Covalent Screening Library
Anti-Lung Cancer Compound Library

生物活性

CDDO-3P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-3P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model^[1]. CDDO-3P-Im is a orally active necroptosis inhibitor that can be used for the research of ischemia/reperfusion (I/R)^[2].

体外研究
(In Vitro)

CDDO-3P-Im (30-100 nM; 4 days) induces differentiation of U937 cells at 30 nM^[1].
CDDO-3P-Im suppresses NO production in RAW264.7 cells with an IC₅₀ of 4.3 nM^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	U937 cells
Concentration:	30 nM, 100 nM
Incubation Time:	4 days
Result:	Induced differentiation of U937 cells at 30 nM.

体内研究
(In Vivo)

CDDO-3P-Im is more stable than CDDO-Im in pharmacokinetic studies^[1].
CDDO-3P-Im significantly elevates heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo^[1].
CDDO-3P-Im (50-200 mg/kg; diet; for 16 weeks) decreases the number, the size and the severity of tumors in A/J mice^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seven week-old female A/J mice^[1]
Dosage:	50 mg/kg, 200 mg/kg
Administration:	Diet; for 16 weeks
Result:	Decreased the number, the size and the severity of tumors.

分子量

618.81

Formula

C₃₉H₄₆N₄O₃

CAS 号

1883650-95-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 250 mg/mL (404.00 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6160 mL	8.0800 mL	16.1600 mL
5 mM	0.3232 mL	1.6160 mL	3.2320 mL
10 mM	0.1616 mL	0.8080 mL	1.6160 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (3.36 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.36 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

参考文献

[1]. Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47.

[2]. Yuanyuan Wang, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2020 Nov 21;113030.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDDO-3P-Im

发表于2024年2月3日由上海金畔生物科技有限公司

CDDO-3P-Im 纯度: 98.19%

CDDO-3P-Im Chemical Structure

CAS No. : 1883650-95-0

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥3810	In-stock
5 mg	￥2800	In-stock
10 mg	￥4500	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

CDDO-3P-Im 相关产品

•相关化合物库:

Covalent Screening Library Plus
Bioactive Compound Library Plus
Apoptosis Compound Library
Anti-Cancer Compound Library
Covalent Screening Library
Anti-Lung Cancer Compound Library

生物活性

体外研究
(In Vitro)

CDDO-3P-Im (30-100 nM; 4 days) induces differentiation of U937 cells at 30 nM^[1].
CDDO-3P-Im suppresses NO production in RAW264.7 cells with an IC₅₀ of 4.3 nM^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	U937 cells
Concentration:	30 nM, 100 nM
Incubation Time:	4 days
Result:	Induced differentiation of U937 cells at 30 nM.

体内研究
(In Vivo)

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seven week-old female A/J mice^[1]
Dosage:	50 mg/kg, 200 mg/kg
Administration:	Diet; for 16 weeks
Result:	Decreased the number, the size and the severity of tumors.

分子量

618.81

Formula

C₃₉H₄₆N₄O₃

CAS 号

1883650-95-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 250 mg/mL (404.00 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6160 mL	8.0800 mL	16.1600 mL
5 mM	0.3232 mL	1.6160 mL	3.2320 mL
10 mM	0.1616 mL	0.8080 mL	1.6160 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (3.36 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.36 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

参考文献

[1]. Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47.

[2]. Yuanyuan Wang, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2020 Nov 21;113030.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

whatman (沃特曼)

英国沃特曼 Millipore PALL中国代理商金畔官网

标签归档：cddo

CDDO-EA(Synonyms: CDDO ethyl amide; TP319; RTA 405)

CDDO-EA 相关产品

•相关化合物库:

Bardoxolone(Synonyms: CDDO; RTA 401)

Bardoxolone 相关产品

•相关化合物库:

CDDO-Im(Synonyms: RTA-403; TP-235; CDDO-Imidazolide)

CDDO-Im 相关产品

•相关化合物库:

CDDO-2P-Im

CDDO-2P-Im 相关产品

•相关化合物库:

CDDO-3P-Im

CDDO-3P-Im 相关产品

•相关化合物库:

CDDO-3P-Im

CDDO-3P-Im 相关产品

•相关化合物库: